
Peptide Pools in Neo-antigen Therapy & Personalized Medicine for Cancer!
Published on 09/10/2024
Harnessing the Power of PepMix™ in Personalized Immune Therapies
In the rapidly evolving field of cancer treatment, personalized immune therapies are at the forefront of innovation. They tailor treatment to the individual characteristics of each patient’s tumor, offering a more targeted and effective approach. One of the key components driving this revolution is the use of neo-antigens—unique peptides that arise from tumor-specific mutations and are not present in normal tissue. Neo-antigens serve as ideal targets for personalized immune therapies, and our PepMix™ peptide pools play a crucial role in this process.
Personalized Immune Therapies
Personalized Immune Therapies including adoptive cell therapies such as dendritic cell therapies or CAR-T cell therapy, represent cutting-edge approaches where the patient’s own immune cells are engineered or stimulated to recognize and attack cancer cells. For instance, in CAR-T cell therapies, T-cells are extracted from the patient, genetically modified to recognize neo-antigens, and then expanded and reinfused into the patient to target the tumor. Dendritic cell therapies involve loading dendritic cells with neoantigens to prime the immune system, enhancing the body’s ability to recognize and destroy cancer cells.
PepMix™: The Key to Unlocking Neoantigen-Based Therapies
PepMix™ peptide pools are specifically designed to stimulate and expand antigen-specific T cells. JPT Peptide Technologies is able to synthesize peptides and peptide pools for any antigen including neo-antigens making them accessible for the expansion of dendritic cells, CIK and NK cells as well as TILs to be used for adoptive cell therapy. Additionally, PepMix Peptide pools are used to measure immunogenicity of viral vectors used for gene therapy e.g. CAR therapies, this avoiding unwanted and harmful immune responses.
References
Our PepMix™ products have been utilized in several high-impact studies, demonstrating their efficacy in neoantigen therapy. The published studies underscore the critical role of PepMix™ in advancing personalized immune therapies.
- Quach et al., Molecular Therapy: Oncology (2024)
- Wang et al., Signal Transductions and Targeted Therapy (2024)
- Jacques et al., Cancers (2024)
- Musher et al., The Lancet Oncology (2024)
- Mandal et al., Nature Cancer (2023)
- Najafabadi et al., BMC Immunology (2022)
- Lulla et al., Blood (2021)
- Lammoglia Cobo et al., Cytotherapy (2022)
- Leen et al., US Patent App. 15/905,176, (2018)
Application Notes by our Customers:
- “Developing Multi‐HIV Antigen Specific T Cells as a Component of a Cure Strategy” S. Lam, C. R. Cruz and C. Bollard
- “PepMix™ Peptide Pools for Clinical Applications: T-Cell Therapy for Viral Infections after Hematopoietic Stem Cell Transplant” J.M. Keirnan, C.M. Rooney, and A.M. Leen
- “Peptide-Stimulated Expansion of VirusSpecific T-Cells for Preventative Treatment after Allogeneic Stem Cell Transplantation” R. Gary, M. Aigner, A. Moosmann and A. Gerbitz
- “Qualification and Use of Peptide Libraries for Clinical Trial Immunomonitoring” J. H. Cox and P. Hayes
- “Characterization of the Aspergillus‐Specific T‐Cell Response by Using Crf1 and Catalase1 Overlapping Peptides” H. Jolink and M.H.M. Heemskerk
Clinical Grade PepMix™: The Ideal Solution for Cell Therapies
At JPT, we are committed to providing the highest quality products to support cutting-edge research and clinical applications. Our CGP (Clinical Grade Peptides) PepMix™ is specifically designed to meet the rigorous demands of cell therapies. Neoantigen peptides are considered a raw material in such therapeutic procedures and not the final product, so do not require a GMP grade production. Our CGP (Clinical Grade Peptides) allows to reduce costs and meet critical raw material requirements, while manufacturing under stringent quality control processes, ensuring consistency, purity, and compliance with regulatory standards. Audits are welcome!
Why Choose JPT’s PepMix™ for Personalized Immune Therapy?
- Quick and Reliable Production: We understand that time is of the essence in personalized medicine. Our efficient production processes ensure that you receive your PepMix™ peptide pools quickly, enabling timely and effective treatment.
- Regulatory Compliance: Our CGP grade PepMix™ meets the stringent requirements set forth by regulatory bodies such as the FDA, ensuring that the highest quality products available support your research and therapies.
- Proven Efficacy: With multiple case studies published in leading scientific journals, our PepMix™ peptide pools have been proven effective in the development of personalized cancer therapies.
For more information on how our CGP grade PepMix™ can enhance your research or to discuss regulatory considerations further, please contact us. Our team of experts, including regulatory specialists, is available to answer any questions you may have.
Conclusion
As personalized medicine continues to transform the landscape of cancer treatment, the role of neo-antigens and tailored therapies becomes increasingly critical. JPT’s PepMix™ peptide pools are at the forefront of this transformation, providing the tools needed to unlock the full potential of personalized immune therapies. Whether you are developing vaccines or adoptive cell therapies, our PepMix™ offers the reliability, quality, and speed necessary to drive your research forward.